BNP Paribas Financial Markets
GPCR icon

BNP Paribas Financial Markets’s Structure Therapeutics GPCR Stock Holding History

BNP Paribas Financial Markets’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$954K Buy
17,781
+6,902
+63% +$305K ﹤0.01% 3346
2026
Q1 		$524K Buy
10,879
+2,133
+24% +$146K ﹤0.01% 3564
2025
Q4 		$608K Sell
8,746
-81,685
-90% -$3.34M ﹤0.01% 3466
2025
Q3 		$2.53M Buy
90,431
+24,595
+37% +$490K ﹤0.01% 2450
2025
Q2 		$1.37M Buy
65,836
+61,318
+1,357% +$1.35M ﹤0.01% 2724
2025
Q1 		$78.2K Sell
4,518
-6,700
-60% -$164K ﹤0.01% 4131
2024
Q4 		$304K Buy
+11,218
New +$398K ﹤0.01% 3618

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

BNP Paribas Financial Markets's GPCR Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Structure Therapeutics (GPCR) stake by 63% in Q2 2026, buying an estimated $305K and bringing the position to 17,781 shares worth $954K. The position accounts for ﹤0.01% of the portfolio, ranked #3346.

BNP Paribas Financial Markets first reported a position in GPCR in Q4 2024 and has held it in 7 quarters since. The position peaked at $2.53M in Q3 2025. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • BNP Paribas Financial Markets held 17,781 shares of Structure Therapeutics worth $954K as of Q2 2026.
  • BNP Paribas Financial Markets bought 6,902 Structure Therapeutics shares in Q2 2026, an estimated $305K.
  • Structure Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3346 holding.
  • BNP Paribas Financial Markets first reported a position in Structure Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Structure Therapeutics position peaked at $2.53M in Q3 2025.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.